Gavín, Olga
Grandes, Jesús
García, Ma Almudena
Marzo, Cristina
Curcio, Alejandro
Arístegui, Rosa
González, Marta
Cerezo-Manchado, Juan José
Funding for this research was provided by:
Daiichi-Sankyo Spain
Article History
First Online: 27 June 2020
Compliance with ethical standards
:
: Dr. Cerezo-Manchado has received a speaker honorarium from Bayer, Pfizer, Daichii Sankyo and Boehringer Ingelheim. Dr. Marzo has received speaker honorarium from Daichii Sankyo, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Rovi and LeoPharma. She has also participated in advisory boards sponsored by Boehringer Ingelheim, CSL Behring and Roche. Dr. Gavín has received a speaker honorarium from Bayer, Pfizer, Daichii Sankyo, Boehringer Ingelheim., Bristol-Myers Squibb, Pfizer, Rovi, Sanofi and LeoPharma. She has also participated in advisory boards sponsored by Boehringer Ingelheim, Pfiser and Bristol-Myers Squibb. R Arístegui and M González are members of the staff of Daiichi Sankyo Spain. Dr. Grandes, Dr. García and Dr. Curcio declare do not have conflict of interests for this work.
: The study was classified as EPA-OD (Post-authorisation Study, Other designs) by the AEMPS and evaluated and approved by the reference Clinical Research Ethics Committee (CEIm) of the Hospital de Fuenlabrada (Madrid), as well as the CEIms of the participating hospitals, as needed.
: All the patients and caregivers were informed by the investigators about the study purposes and signed the informed consent prior to study inclusion.
: All authors agree with the publication of the manuscript.
: Not applicable.